• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
• 3. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 4. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 5. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles Benzimidazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles

Professional Introduction to 7-(Trifluoromethyl)-1H-benzo[d]imidazol-2-amine (CAS No. 10057-45-1)

7-(Trifluoromethyl)-1H-benzo[d]imidazol-2-amine is a significant compound in the field of pharmaceutical chemistry, renowned for its versatile applications in drug development and medicinal research. This compound, identified by the CAS number 10057-45-1, belongs to the benzo[d]imidazole class, which has garnered considerable attention due to its structural framework and biological activities. The presence of a trifluoromethyl group in its molecular structure enhances its pharmacological properties, making it a valuable candidate for further exploration in therapeutic interventions.

The benzo[d]imidazole scaffold is a core structural motif found in numerous bioactive molecules, exhibiting a wide range of pharmacological effects. These effects include anti-inflammatory, antimicrobial, and anticancer properties, which have been extensively studied in academic and industrial research settings. The introduction of fluorine atoms into the molecular structure, particularly the trifluoromethyl group, has been shown to modulate the electronic properties of the molecule, thereby influencing its binding affinity and metabolic stability. This modification has been pivotal in enhancing the efficacy and selectivity of drugs derived from this scaffold.

In recent years, there has been a surge in research focused on developing novel compounds with improved pharmacokinetic profiles. 7-(Trifluoromethyl)-1H-benzo[d]imidazol-2-amine has emerged as a promising candidate in this context due to its ability to interact with various biological targets. The trifluoromethyl group not only enhances lipophilicity but also contributes to metabolic stability, making it an attractive moiety for drug design. Furthermore, studies have demonstrated that compounds incorporating this group often exhibit greater resistance to enzymatic degradation, thereby prolonging their half-life in vivo.

The pharmaceutical industry has been particularly interested in leveraging the benzo[d]imidazole scaffold for the development of anticancer agents. Research has shown that derivatives of this compound can inhibit key enzymes involved in tumor proliferation and angiogenesis. For instance, modifications at the 2-amino position, as seen in 7-(Trifluoromethyl)-1H-benzo[d]imidazol-2-amine, have been found to enhance binding affinity to target proteins such as kinases and transcription factors. These interactions are critical for disrupting cancer cell signaling pathways and inducing apoptosis.

The synthesis of 7-(Trifluoromethyl)-1H-benzo[d]imidazol-2-amine involves multi-step organic reactions that require precise control over reaction conditions and reagent selection. Advanced synthetic methodologies have been employed to optimize yield and purity, ensuring that the final product meets stringent pharmaceutical standards. Techniques such as palladium-catalyzed cross-coupling reactions and fluorination methods have played a crucial role in constructing the desired molecular framework efficiently.

Evaluation of the pharmacological properties of 7-(Trifluoromethyl)-1H-benzo[d]imidazol-2-amine has revealed its potential as an intermediate in the synthesis of more complex drug molecules. Preclinical studies have demonstrated its ability to modulate inflammatory responses by inhibiting cytokine production and reducing oxidative stress. Additionally, its interaction with specific receptors has been explored for potential applications in treating neurological disorders characterized by abnormal receptor activity.

The benzo[d]imidazole class of compounds continues to be a subject of intense research due to their broad spectrum of biological activities. The incorporation of functional groups such as the trifluoromethyl moiety has further expanded their therapeutic potential. By fine-tuning the molecular structure, researchers aim to develop drugs that are not only more effective but also possess improved safety profiles. This approach aligns with the broader goal of precision medicine, where individual patient characteristics are taken into account when designing therapeutic strategies.

In conclusion, 7-(Trifluoromethyl)-1H-benzo[d]imidazol-2-amine (CAS No. 10057-45-1) represents a significant advancement in pharmaceutical chemistry. Its unique structural features and biological activities make it a valuable asset in drug discovery efforts aimed at addressing various diseases. As research progresses, this compound is expected to contribute significantly to the development of novel therapeutic agents that meet the evolving needs of patients worldwide.

• 326-55-6(5-Trifluoromethyl-1H-benzimidazole)
• 1258652-66-2(8-(Trifluoromethyl)quinazolin-2-amine)
• 754241-57-1(5-(trifluoromethyl)-1H-Benzimidazole-7-methanamine)
• 384-32-7(1H-Benzimidazole,2-methyl-7-(trifluoromethyl)-)
• 10057-46-2(6-(trifluoromethyl)-1H-1,3-benzodiazol-2-amine)
• 1804098-55-2(4-Hydroxymethyl-7-trifluoromethyl-1H-benzimidazole)
• 1805870-56-7(6-Hydroxymethyl-4-trifluoromethyl-1H-benzimidazole)
• 1423033-54-8(5-(trifluoromethyl)-1H-1,3-benzodiazol-2-amine hydrochloride)
• 1803896-60-7(2-Fluoro-4-trifluoromethyl-1H-benzimidazole)
• 392-11-0(4-(Trifluoromethyl)benzimidazole)